| Autor: |
CHEN Shuangqing, WU Wenbo, HAN Chaohui, CAO Shumin, ZHANG Xiaopeng, DUAN Guochen |
| Jazyk: |
čínština |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Zhongliu Fangzhi Yanjiu, Vol 49, Iss 10, Pp 1065-1070 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1000-8578 |
| DOI: |
10.3971/j.issn.1000-8578.2022.22.0145 |
| Popis: |
With the research progress on the biology and pathogenesis of cancer, immune checkpoint inhibitors (ICIs) have come into being, bringing a new hope for the survival of patients with advanced cancer and opening a new era of cancer immunotherapy. However, with the wide application of immunotherapy in clinical practice, ICI-related adverse events (irAEs) have gradually emerged and are widely known by first-line clinicians. ICIs primarily activate T cells that can attack normal tissues and organs in the body and cause a variety of adverse reactions. Checkpoint inhibitor pneumonitis (CIP) is one of the rare complications with poor prognosis in irAEs. This article reviews the therapeutic mechanism of some ICIs; the incidence, risk factors, pathogenesis, and clinical and imaging manifestations of CIP; and the classification and treatment management of CIP. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
